Dr Jasmine Kaur
GRIFFITH UNIVERSITY, QUEENSLAND, AUSTRALIA
-
Good and bad extracellular vesicles in health and disease
Associate Professor Joy Wolfram has joint appointments in the School of Chemical Engineering and the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland, and through her work at the AIBN, she aims to develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat life-threatening diseases that are major causes of death globally, including cardiovascular disease, kidney disease, and breast cancer.
-
Pancreatic and lung cancers driven by mutations in the cancer gene KRAS
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors). -
Supportive care for people living with or beyond cancer treatment
Dr Hannah Wardill is a Hospital Research Foundation Fellow and lead of the Supportive Oncology Research Group (SORG), in the School of Biomedicine, University of Adelaide and Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI). She is an Executive Board Member of the Multinational Association for Supportive Care in Cancer / International Society for Oral Oncology (MASCC/ISOO) and Chair of both MASCC/ISOO Patient Partnership Committee & the Palliative Care Clinical Studies Collaborative (PaCCSC) Cancer Symptom Trials (Gut Dysfunction Node; supported by Cancer Australia).
